

# PRIOR AUTHORIZATION CRITERIA

## BRAND NAME (generic)

**LIDODERM**  
(lidocaine patch 5%)

**ZTLIDO**  
(lidocaine topical system)

**Status: CVS Caremark Criteria**

**Type: Initial Prior Authorization with Quantity Limit**

## POLICY

### FDA-APPROVED INDICATIONS

#### **Lidoderm**

Lidoderm is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to **intact skin**.

#### **ZTLido**

ZTLido (lidocaine topical system) 1.8% is indicated for relief of pain associated with post-herpetic neuralgia (PHN).

#### Compendial Uses

Pain associated with diabetic neuropathy<sup>4,5,8</sup>

Pain associated with cancer-related neuropathy<sup>4,6,7</sup>

### COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for any of the following: A) Pain associated with post-herpetic neuralgia, B) Pain associated with diabetic neuropathy, C) Pain associated with cancer-related neuropathy (including treatment-related neuropathy [e.g. neuropathy associated with radiation treatment or chemotherapy])

Quantity Limits apply.

90 patches/25 days or 270 patches/75 days\*

*\*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*

### REFERENCES

1. Lidoderm [package insert]. Malvern, PA: Endo Pharmaceuticals Inc.; January 2020.
2. ZTLido [package insert]. San Diego, CA: Scilex Pharmaceuticals Inc.; November 2018.
3. Lexicomp Online, Lexi-Drugs Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed August 2020.
4. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed August 2020.
5. Barbano RL, Herrmann DN, Hart-Gouleau S, et al: Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. *Arch Neurol.* 2004; 61:914-918.
6. National Comprehensive Cancer Network (NCCN) Guidelines: Adult Cancer Pain V1.2020. National Comprehensive Cancer Network. Fort Washington, PA. 2008. Available from URL: [http://www.nccn.org/professionals/physician\\_gls/PDF/pain.pdf](http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf). Accessed August 2020.

7. Vadalouca A, Raptis E, Moka E, et al. Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature. World Institute of Pain. *Pain Practice*. 2011; 12(3):219-251.
8. Bril V., England J., Franklin G.M., et al. Evidence-based guideline: Treatment of painful diabetic neuropathy. *Neurology*. 2011;76;1758-1765. Available at [www.neurology.org](http://www.neurology.org). Accessed August 2020.
9. Derry S, Wiffen PJ, Moore RA, et al. Topical lidocaine for neuropathic pain in adults (Review). *Cochrane Database Syst Rev* 2014. doi: 10.1002/14651858.CD010958.